Dyadic International (NASDAQ:DYAI) Stock Passes Above 50-Day Moving Average – Should You Sell?

Dyadic International Inc. (NASDAQ:DYAI) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.94 and traded as high as $1.1550. Dyadic International shares last traded at $1.08, with a volume of 83,162 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Price Performance

The company has a market capitalization of $37.17 million, a price-to-earnings ratio of -4.43 and a beta of 1.12. The business has a 50-day moving average price of $0.95 and a two-hundred day moving average price of $0.86. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. As a group, research analysts anticipate that Dyadic International Inc. will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. Marathon Capital Management increased its stake in shares of Dyadic International by 142.9% in the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after buying an additional 50,000 shares during the period. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the third quarter valued at about $190,000. Finally, Bank of America Corp DE raised its position in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. 27.95% of the stock is owned by institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.